New clinical trial data presented at ObesityWeek 2015 showed that treatment with Saxenda (liraglutide; Novo Nordisk) in combination with a reduced-calorie diet and increased physical activity led to significant and sustained weight loss over 3 years vs. a reduced-calorie diet and increased physical activity alone (placebo).
The 3-year extension part of the Phase 3a SCALE™ (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and Pre-diabetes study included 2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline.
At Week 160, patients treated with Saxenda had an average body weight loss of 6.1% from baseline vs. 1.9% for placebo (P<0.0001). Weight loss ≥5% was seen in 49.6% of patients treated with Saxenda vs. 23.7% for placebo (P<0.0001). Data also showed 24.8% of patients lost >10% of their body weight with Saxenda vs. 9.9% with placebo (P<0.0001).
The extension trial achieved the primary endpoint showing that continued treatment with Saxenda in combination with a reduced-calorie diet and increased physical activity delayed the onset of type 2 diabetes vs. placebo.
Saxenda injection, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available as prefilled multi-dose pens delivering doses of 0.6mg, 1.2mg, 1.8mg, 2.4mg, or 3mg (6mg/mL, 3mL) in 3- and 5-count cartons.
For more information call (800) 727-6500 or visit Saxenda.com.